Compare HELP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HELP | NERV |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | 50 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.0M | 210.1M |
| IPO Year | N/A | 2014 |
| Metric | HELP | NERV |
|---|---|---|
| Price | $6.59 | $4.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $51.50 | $10.50 |
| AVG Volume (30 Days) | ★ 1.5M | 379.3K |
| Earning Date | 07-01-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $1.76 |
| 52 Week High | $8.55 | $12.46 |
| Indicator | HELP | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 62.60 | 43.42 |
| Support Level | $5.77 | $4.30 |
| Resistance Level | $7.06 | $4.59 |
| Average True Range (ATR) | 0.53 | 0.47 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 70.36 | 21.05 |
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.